3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
3
Terminated
2
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
50
Pancreatic Neoplasms
14
Neoplasms
11
Lung Neoplasms
11
Neoplasm Metastasis
7
Breast Neoplasms
6
Brain Neoplasms
6
Head and Neck Neoplasms
4
Gliosarcoma
4
Glioblastoma
4
Carcinoma, Hepatocellular
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Neuroendocrine Tumors
3
Colorectal Neoplasms
3
Carcinoma, Squamous Cell
3
Prostatic Neoplasms
2
Oligodendroglioma
2
Non-Squamous Non-Small Cell Lung Cancer
2
Glioma
2
Familial ependymoma
2
Esophageal Neoplasms
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma
2
Carcinoid Tumor
2
Astrocytoma
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Interventions
Carboplatin
7
Pemetrexed
5
pembrolizumab
4
Gemcitabine
4
osimertinib
3
Sorafenib
3
Paclitaxel
3
Interleukin-2
3
Cyclophosphamide
3
Cisplatin
3
seocalcitol
2
selinexor
2
patritumab
2
liposomal doxorubicin
2
interferon gamma-1b
2
fludarabine
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Irinotecan
2
Erlotinib Hydrochloride
2
DNA
2
Celecoxib
2
Capecitabine
2
Bleomycin
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
volociximab
1
thioredoxin reductase inhibitor AM12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma
×
Erlotinib Hydrochloride
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts
NCT00673049
2013-07-24
NSCLC
Pfizer
Phase 3
Terminated
583 enrolled
11 charts